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Abstract: 
Phase II and III clinical trials demonstrated modest anti- tumor activity of Binimetinib 
(MEK162) - a potent allosteric inhibitor of MEK1 and MEK2- in patients with advanced 
NRAS mutant melanoma. 
The analysis of the NEMO study in NRAS mutated melanoma, has shown that pre-
treatment with immunotherapy improved the outcome of binimetinib therapy. 
We discuss this finding in the context of in vitro and in vivo effects of MEK inhibition on 
immuno-critical pathways and interactions. 
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Introduction 
Cutaneous melanomas are malignancies that originate from melanocytes, which derive 
from neural crest cells. Recently, the genetic and genomic landscapes of melanoma were 
investigated by next generation sequencing and have revealed several cancer-driving 
oncogenes. Most, if not all cutaneous melanomas present genetic alterations, resulting in 
an increased activity of the mitogen-activated protein kinase (MAPK) pathway, including 
mutations of BRAF, NRAS and RAC1. In addition, mutations can inactivate important 
tumor suppressor genes, such as neurofibromin 1 (NF1), ARID2, tumor protein p 53 
(TP53) and cyclin-dependent kinase Inhibitor 2A (CDKN2A), some of which modulate 
MAPK pathway activity [1].  
In vitro investigations have demonstrated that detection of the MAPK pathway activating 
BRAF or NRAS mutations, predicts the sensitivity to MEK inhibitors, which interfere 
with the activity of the kinases MEK1 and MEK2 [2] [3]. Consequently, MEK kinase 
inhibitors have been investigated in several clinical trials in metastatic cutaneous 
melanomas.  
 
Clinical data 
Already between July 2006 and June 2007, one of the first larger clinical trials in 
advanced melanoma compared the efficacy of orally administered selumetinib and 
temozolomide in chemotherapy-naïve patients. Selumetinib (AZD6244/ARRY-142886) 
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is an orally available, potent, selective, allosteric inhibitor of MEK1/2 with preclinical 
antitumor activity in melanoma (16). It was the first multicenter, randomized study 
conducted in patients with melanoma assessed for both BRAF and NRAS mutations. No 
significant difference in progression-free survival (PFS) was observed between 
selumetinib and temozolomide in patients unselected for BRAF or NRAS mutations. 
However, five out of six patients with partial response (PR) to selumetinib presented 
BRAF mutant tumors [4] suggesting that molecular profiling would help to identify 
patients who will benefit from this therapy. 
This hypothesis was tested in a large phase III clinical trial investigating the MEK 
inhibitor (MEKi) trametinib in BRAF-mutated advanced melanoma in comparison to 
chemotherapy [5]. The outcome of this study was a median PFS of 4.8 months in the 
trametinib arm and 1.5 months in the chemotherapy arm. The superiority of MEKi was 
reflected in the hazard ratio (HR) of 0.45 (95% CI, 0.33 - 0.63; p<0.001). The 6-month 
overall survival (OS) was 81% in the trametinib arm and 67% in the chemotherapy arm. 
The HR for death was 0.54 (95% CI, 0.32 - 0.92; p<0.014) in the trametinib arm versus 
the chemotherapy arm, despite crossover which demonstrated the impressive efficacy of 
MEKi in BRAF-mutated melanoma. 
 
Binimetinib (MEK162) is a potent, selective, non–adenosine triphosphate (ATP)–
competitive allosteric inhibitor of MEK1 and MEK2. It has demonstrated growth 
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inhibition of NRAS- and BRAFV600E-mutant melanoma in various preclinical models in 
vitro and in vivo. Binimetinib was investigated in a phase II clinical trial, that enrolled 30 
patients with NRAS-Q61-mutated  and 41 patients with BRAF-mutated melanoma into the 
45 mg arm [6]. Pharmacokinetic profiling revealed that binimetinib is well absorbed, with 
a median Tmax of 1.48 hours on day 15 with moderate interpatient variability. Partial 
response (PR) was observed in 6/30 (20% [95% CI, 8–39]) of patients with NRAS 
mutations. The median response duration was approximately eight weeks.  
The median PFS was 3.7 (95% CI, 2.5–5.4) months for patients with NRAS-mutated 
melanoma. This modest, but clinically meaningful effect in the NRAS-mutated advanced 
melanoma population was the rationale to develop a phase III clinical trial called NEMO 
(NRAS melanoma and MEK inhibitor) in this genetically defined patient population with 
a high medical need. All the more so after the failure of immunotherapy, which is the 
preferred 1st line treatment option in patients with metastatic NRAS-mutated melanoma 
today [7]. 
The NEMO protocol is a randomized phase III, open-label, multicenter, two-arm clinical 
trial, comparing binimetinib to dacarbazine in patients with advanced unresectable or 
metastatic melanoma harboring NRAS mutations. Stratification factors included 
performance status, stage and prior immunotherapy. 
Between July 2013 and April 2015, 402 patients were enrolled, 269 of which were 
randomized to binimetinib and 133 to a dacarbazine-arm. Binimetinib achieved a superior 
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PFS (HR 0.62, 95% CI, 0.47 – 0.80; p<0·001). Median PFS was 2·8 months (95% CI, 2.8 
– 3.6) for binimetinib and 1.5 months (95% CI, 1.5 – 1.7) for dacarbazine. Median OS 
was 11·0 months (8·9–13·6) for binimetinib and 10.1 months (95% CI, 7.0 – 16.5) for 
dacarbazine (HR 1.00 [0.75 – 1.33]; p=0.499). 
Binimetinib treatment was associated with a higher confirmed overall response rate 
(ORR) compared with dacarbazine (15.2% [95% CI, 11.2% – 20.1%; n=41] vs 6.8% 
[95% CI, 3.1% – 12.5%; n=9]; p=0.015, two-sided test). Four patients (1.5%) in the 
binimetinib arm and no patients in the dacarbazine arm achieved a complete response 
(CR). Additionally, binimetinib achieved a higher disease control rate than dacarbazine 
with 58.4% in the binimetinib arm vs 24.8% in the dacarbazine arm. 
PFS in most pre-specified patient subgroups was consistent with the overall population, 
including high risk subgroups such as patients with elevated lactate dehydrogenase 
(LDH) serum levels or advanced disease stage (M1c). In the population of patients 
pretreated with immunotherapy, median PFS was longer for those who received 
binimetinib vs dacarbazine (5.5 months vs 1.6 months). Further, within this stratum, the 
confirmed ORR per central review was 15.8% vs 3.6%, and the median duration of 
response was 11.1 months vs 4.1 months, in the binimetinib vs dacarbazine arms, 
respectively (Dummer R. et al. Binimetinib versus dacarbazine in patients with advanced 
NRAS-mutant melanoma (NEMO): a multicentre, open-label, 
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randomised, phase 3 trial_Lancet Oncology Published online March 8, 2017). Since 
nowadays most advanced melanoma patients receive immunotherapy as 1st line treatment, 
these data are relevant for the management of this patient population. In order to 
understand these clinical observations, it is reasonable to review preclinical 
investigations.  
 
Preclinical data 
In a recently published report [8] by Brea et al., it was convincingly demonstrated, that 
the inhibition of an over activated MAPK pathway by MEKi or EGFR inhibitors  results 
in the up-regulation of HLA class I molecules in several tumor cell lines. This effect was 
further enhanced in presence of interferon-gamma. It is accompanied by an upregulation 
of key components of the antigen processing machinery including TAP transporters and 
beta2 microglobulin at the mRNA level. 
These data are consistent with the results reported by Liu et al. (2015) [9] who 
investigated BRAF mutant melanoma cells treated with BRAF inhibitors (BRAFi), MEKi 
or both for a period of 6 hours up to two days. They documented an increase in HLA 
class I and II, including non-classical HLA-E expression, an enhanced expression of 
immunomodulating molecules including CD40, CD68, CD70, CD83, GBP1, ICOSLG, 
IL15, IRF1, OX40L, SPP1, STAT1, STAT3, TOX, B7-H3, PDCD2,  and a decrease in 
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expression of immunosuppressive factors such as IL1A, IL8, NT5E, VEGFA and PDL1 
along with a series of other effects on molecules involved in apoptosis.  
 
Long-term exposure (2 weeks) to a MEKi or a pan-BRAFi, exerts different effects 
depending on the phenotype of the tumor cells, as described by Zipser et al [10]. This 
work demonstrates a phenotype switch in MITF expressing tumor cells with an activated 
MAPK pathway, characterized by a change in morphology, increased invasiveness and a 
reduced expression of melanocytic differentiation antigens [10]. The immunological 
consequences of these alterations remain unclear. We assume that immunogenicity might 
be reduced after long-term exposure in contrast to short-term. Deken et al. [11] who 
investigated the impact of the MAPK pathway in a mouse model reported an influx of T-
cells during the 1st week of therapy with a BRAFi alone, and a lesser presence of T-cells 
later on, supporting our hypothesis. Intermittent pulsing of kinase inhibitors might be 
helpful to overcome this problem [12]. 
 
MEKi effect on T-cells 
Given the central role of the MAPK pathway in T-cell receptor signaling, concerns were 
rapidly raised regarding the effect of MEKi on T-cell functions [13] [14] . In 2010, Boni 
et al. showed that unlike BRAFi, MEKi impairs T-cell functions in vitro. They reported a 
decrease in proliferation and viability, as well as a diminished response against melanoma 
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cells when the cultures were grown in presence of MEKi [15] . Further in vitro 
investigation on the effect of MEKi on the different T-cell sub-populations revealed a 
decrease in proliferation in CD8+ and CD4+ T-cells and a concentration-dependent 
decline in the generation of antigen-specific T lymphocytes [16]. The investigation of the 
effect of MEKi on the different T-cell stages revealed a more complex and context-
dependent regulation.  
In 2015, Liu et al. [9] showed contrasts in response depending on the sequence of T-cell 
activation and MEKi treatment. When CD4+ T-cells are dosed with MEKi 24h before 
activation (at clinically relevant concentrations), a transient decrease in proliferation can 
be seen after 3 days of treatment; this effect however dissipates at day 7 [9] . MEK 
inhibition was also reported to limit CD4+ T-cell activation induced apoptosis. 
As opposed to what has been previously observed in vitro, different groups demonstrated 
that the cytotoxic capabilities of T-cells extracted from tumor bearing mice treated with 
MEKi, are not impaired and can respond to re-stimulation ex-vivo by releasing IFNγ [17] 
.  
Since complex interactions between tumor cells and lymphocytes cannot be assessed in 
vitro, further studies were carried out in vivo. In that context, it was clearly established 
that MEKi treatment alone or in combination to BRAFi increased CD8+ tumor infiltration 
in mice [11,17] . Not only was CD8+ T-cell function under MEKi treatment shown not to 
be impeded, but it also seemed to be indispensable for an optimal anti-tumor response. 
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Different groups showed that depletion of CD8+ does not attenuate MEKi treatment 
efficiency [18,19].  
A more recent study from Ebert et al shed more light on the specific action of MEKi, in 
vivo, on different T-cell stages in mice [19]. They first confirmed the activity of MEKi at 
the tumor site by showing a reduction in pERK. Their data corroborated a higher CD8+ 
influx into the tumor upon MEKi treatment, but also illustrated phenotypic differences 
compared to control (vehicle treated) tumor-infiltrating lymphocytes (TILs). TILs from 
MEKi treated mice had a lower ratio of PD-1hi/PD-1low expression compare with control 
and expressed higher levels of T-bet and Eomes, 2 transcription factors controlling CD8+ 
T-cell differentiation towards effector functions.  However, the analysis of the lymph 
nodes revealed a different behavior of T-cells upon MEKi treatment before priming. 
Indeed, the treatment prevented the expansion of naïve CD8+ and the up-regulation of T-
bet in response to stimulation, but did not deplete them.  
As described for CD4+ T-cells, MEKi seems to prevent activation-induced apoptosis in 
CD8+ T-cells. Antigen-experienced T-bethi CD8+ T-cells have been shown to be 
particularly vulnerable to this fate (via up-regulation of Nur77 and caspase activation) but 
the addition of MEKi leads to an accumulation of those tumor-specific CD8+ T-cells. 
Finally, the authors proved that this enriched pool of antigen-specific T-cells is also 
capable of killing target cells and that MEKi treatment does not affect this process. 
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Inflammatory skin reactions are frequent in patients treated with MEKi [4,20]. In the 
normal epidermis, active EGFR mediated MAPK pathway activation is mainly seen in 
the basal keratinocytes. The sudden interruption of this signaling pathway by MEKi 
results in an acute keratinocyte stress response with an upregulation of p53 including a 
disturbed epidermal homeostasis associated with inflammation and tissue damage caused 
by the influx of neutrophils and lymphocytes. Similar changes of the microenvironment 
might also occur in the tumor microenvironment  
 
Discussion: Comparison to BRAFi in BRAF-mutated melanoma   
As outlined above, MEKi treatment confers distinct effects on melanoma cells that 
influence tumor cell immunogenicity, microenvironment, and the host immune responses 
via interference with the MAPK pathway in various cell types.  Before the advent of MEKi 
in large-scale clinical trials, selective inhibitors of the BRAF molecule had already been 
shown to induce robust tumor responses in patients with BRAF-mutated metastatic 
melanoma [21,22]. The antitumor effect of BRAFi was primarily attributed to the direct 
blockade of MAP kinase signaling. Subsequently, evidence has emerged that BRAF 
inhibition additionally elicits various immunological changes affecting the tumor-host 
interaction, which may also contribute to the beneficial effects of BRAFi in the BRAF-
mutant patient population. In BRAF-mutated tumor cells, the immunolo-modulatory effects 
induced by BRAFi are to some extent in line with those described for MEKi above. These 
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effects have been demonstrated both in vitro and in vivo and include an increased 
expression of melanoma-associated antigens, a decreased release of immunosuppressive 
cytokines (IL6, IL8, IL-1, VEGF) by the tumor as well as an enhanced tumor infiltration 
by CD4+ and CD8+ TILs [23-25]. However, in BRAF-wild type cells, BRAFi induce 
contrasting immunological modifications , mostly due to the paradoxical activation of the 
MAPK pathway which exclusively occurs with BRAFi treatment, in a CRAF-dependent 
manner [26]. This mechanism is thought to further enhance effector function of T- or NK- 
cells by inducing oligoclonal expansion [27]. On the other hand, paradoxical MAPK 
pathway activation has been associated with an increased expression of T-cell exhaustion 
markers such as PD-1 and TIM3 on T-cells as well as PD-L1 on tumor cells, which 
attenuates immune response [23]. Moreover, it has been suggested that paradoxical MAPK 
pathway activation may increase autoimmunity and frequency of immune-related adverse 
events by over-activating T-cells, especially when combining BRAFi with immunotherapy, 
and, conversely, may lead to enhanced function of regulatory immune cells such as 
myeloid-derived suppressor cells or T regulatory cells. Intriguingly, these negative immune 
effects of BRAFi monotherapy are partially reversed by MEK-inhibition. That is, increased 
surface expression of PD-L1 in BRAFi resistant melanoma cell lines is diminished after 
treatment with a selective MEKi [28]. In a more clinical context, tumor samples from 
patients treated with BRAFi monotherapy showed, after an initial increase in the first weeks 
of treatment, a decrease in melanoma-associated antigen expression that could reflect the 
phenotype switch in vivo and reduced T-cell infiltration at the time of disease progression. 
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These changes are subsequently  reverted by the addition of a MEKi [23]. As discussed 
earlier in this review, the recently described potentially protective effect of MEKi on 
antigen-experienced CD8+ cells may as well contribute to this clinical phenomenon [19].  
Taken together, these findings give a strong rationale to combine MAPK-pathway 
inhibitors (either BRAF-/MEKi combination in BRAF-mutated tumors or single agent 
MEK-I in BRAF Wt tumors) with immunotherapy. Randomized clinical trials investigating 
the addition of PD1-/PDL1-antibodiesto targeted therapy have been initiated. Early clinical 
results of these combinations demonstrated feasibility and tolerability in conjunction with 
an impressive anti-tumor efficacy (Sulllivan R et al, oral presentation SMR Congress 2016; 
Infante J et al, oral presentation SMR Congress 2016.  ClinicalTrials.gov Identifier: 
NCT02908672; ClinicalTrials.gov Identifier: NCT02130466).     
 
Conclusion 
The mechanisms of immunotherapies using checkpoint inhibitors are complex.  They 
typically result in the activation of primed T-cells in vivo, however, in a chronically 
inflamed environment such as the tumor, the T-cell are prone to exhaustion and 
apoptosis. Addition of MEKi might reduce this risk. 
Moreover, MEKi increases the immunogenicity of melanoma cells by upregulating  
immuno-critical molecules including HLA class I, molecules involved in antigen 
processing and cancer antigens, but also reduce suppressive factors such as PD-L1 on 
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tumor cells or immunosuppressive cytokines, at least during the early treatment phase. In 
addition, there is evidence that access of inflammatory cells to the tumor 
microenvironment may be improved in the presence of MEKi. 
These findings may explain the differences observed in MEKi monotherapy in 
immunotherapy naïve versus pretreated patients and provide a strong rationale to develop 
MEKi/immunotherapy combination strategies. Intermittent kinase inhibitor therapy 
deserves specific attention in this context. 
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Figure 1: MEKi may have negative impact on T cell priming but may enhance the 
survival of activated T cells. They can increase cancer antigen presentation and 
immunogenicity of tumor cells. (modified after Chen DS & Mellman I, Immunity 2013, 
33). 
 
 
 
 
 
16 
 
 
 
 
 
 
 
 
 
 
References 
1 Krauthammer M, Kong Y, Bacchiocchi A, Evans P, Pornputtapong N, Wu C, 
McCusker JP, Ma S, Cheng E, Straub R, Serin M, Bosenberg M, Ariyan S, Narayan D, 
Sznol M, Kluger HM, Mane S, Schlessinger J, Lifton RP, Halaban R: Exome sequencing 
identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas. 
Nat Genet 2015 
2 Raaijmakers MI, Widmer DS, Narechania A, Eichhoff O, Freiberger SN, Wenzina 
J, Cheng PF, Mihic-Probst D, Desalle R, Dummer R, Levesque MP: Co-existence of 
BRAF and NRAS driver mutations in the same melanoma cells results in heterogeneity of 
targeted therapy resistance. Oncotarget 2016;7:77163-77174. 
3 Solit DB, Garraway LA, Pratilas CA, Sawai A, Getz G, Basso A, Ye Q, Lobo JM, 
She Y, Osman I, Golub TR, Sebolt-Leopold J, Sellers WR, Rosen N: BRAF mutation 
predicts sensitivity to MEK inhibition. Nature 2006;439:358-362. 
4 Kirkwood JM, Bastholt L, Robert C, Sosman J, Larkin J, Hersey P, Middleton M, 
Cantarini M, Zazulina V, Kemsley K, Dummer R: Phase II, open-label, randomized trial 
of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients 
with advanced melanoma. Clin Cancer Res 2012;18:555-567. 
5 Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, Demidov LV, 
Hassel JC, Rutkowski P, Mohr P, Dummer R, Trefzer U, Larkin JM, Utikal J, Dreno B, 
Nyakas M, Middleton MR, Becker JC, Casey M, Sherman LJ, Wu FS, Ouellet D, Martin 
17 
 
AM, Patel K, Schadendorf D: Improved survival with MEK inhibition in BRAF-mutated 
melanoma. N Engl J Med 2012;367:107-114. 
6 Ascierto PA, Schadendorf D, Berking C, Agarwala SS, van Herpen CM, Queirolo 
P, Blank CU, Hauschild A, Beck JT, St-Pierre A, Niazi F, Wandel S, Peters M, Zubel A, 
Dummer R: MEK162 for patients with advanced melanoma harbouring NRAS or Val600 
BRAF mutations: a non-randomised, open-label phase 2 study. Lancet Oncol 
2013;14:249-256. 
7 Dummer R, Hauschild A, Lindenblatt N, Pentheroudakis G, Keilholz U: 
Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and 
follow-up. Ann Oncol 2015;26 Suppl 5:v126-132. 
8 Brea EJ, Oh CY, Manchado E, Budhu S, Gejman RS, Mo G, Mondello P, Han JE, 
Jarvis CA, Ulmert D, Xiang Q, Chang AY, Garippa RJ, Merghoub T, Wolchok JD, 
Rosen N, Lowe SW, Scheinberg DA: Kinase Regulation of Human MHC Class I 
Molecule Expression on Cancer Cells. Cancer Immunol Res 2016;4:936-947. 
9 Liu L, Mayes PA, Eastman S, Shi H, Yadavilli S, Zhang T, Yang J, Seestaller-
Wehr L, Zhang SY, Hopson C, Tsvetkov L, Jing J, Zhang S, Smothers J, Hoos A: The 
BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and 
in Combination with Immunomodulatory Antibodies Targeting PD-1, PD-L1, and CTLA-
4. Clin Cancer Res 2015;21:1639-1651. 
10 Zipser MC, Eichhoff OM, Widmer DS, Schlegel NC, Schoenewolf NL, Stuart D, 
Liu W, Gardner H, Smith PD, Nuciforo P, Dummer R, Hoek KS: A proliferative 
melanoma cell phenotype is responsive to RAF/MEK inhibition independent of BRAF 
mutation status. Pigment Cell Melanoma Res 2011;24:326-333. 
11 Deken MA, Gadiot J, Jordanova ES, Lacroix R, van Gool M, Kroon P, Pineda C, 
Geukes Foppen MH, Scolyer R, Song JY, Verbrugge I, Hoeller C, Dummer R, Haanen 
JB, Long GV, Blank CU: Targeting the MAPK and PI3K pathways in combination with 
PD1 blockade in melanoma. Oncoimmunology 2016;5:e1238557. 
12 Das Thakur M, Salangsang F, Landman AS, Sellers WR, Pryer NK, Levesque 
MP, Dummer R, McMahon M, Stuart DD: Modelling vemurafenib resistance in 
melanoma reveals a strategy to forestall drug resistance. Nature 2013;494:251-255. 
13 Sharp LL, Schwarz DA, Bott CM, Marshall CJ, Hedrick SM: The influence of the 
MAPK pathway on T cell lineage commitment. Immunity 1997;7:609-618. 
14 D'Souza WN, Chang CF, Fischer AM, Li M, Hedrick SM: The Erk2 MAPK 
regulates CD8 T cell proliferation and survival. J Immunol 2008;181:7617-7629. 
15 Boni A, Cogdill AP, Dang P, Udayakumar D, Njauw CN, Sloss CM, Ferrone CR, 
Flaherty KT, Lawrence DP, Fisher DE, Tsao H, Wargo JA: Selective BRAFV600E 
inhibition enhances T-cell recognition of melanoma without affecting lymphocyte 
function. Cancer Res 2010;70:5213-5219. 
16 Vella LJ, Andrews MC, Pasam A, Woods K, Behren A, Cebon JS: The kinase 
inhibitors dabrafenib and trametinib affect isolated immune cell populations. 
Oncoimmunology 2014;3:e946367. 
17 Hu-Lieskovan S, Mok S, Homet Moreno B, Tsoi J, Robert L, Goedert L, Pinheiro 
EM, Koya RC, Graeber TG, Comin-Anduix B, Ribas A: Improved antitumor activity of 
immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma. Sci Transl 
Med 2015;7:279ra241. 
18 
 
18 Allegrezza MJ, Rutkowski MR, Stephen TL, Svoronos N, Perales-Puchalt A, 
Nguyen JM, Payne KK, Singhal S, Eruslanov EB, Tchou J, Conejo-Garcia JR: 
Trametinib Drives T-cell-Dependent Control of KRAS-Mutated Tumors by Inhibiting 
Pathological Myelopoiesis. Cancer Res 2016;76:6253-6265. 
19 Ebert PJ, Cheung J, Yang Y, McNamara E, Hong R, Moskalenko M, Gould SE, 
Maecker H, Irving BA, Kim JM, Belvin M, Mellman I: MAP Kinase Inhibition Promotes 
T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade. 
Immunity 2016;44:609-621. 
20 Schad K, Baumann Conzett K, Zipser MC, Enderlin V, Kamarashev J, French LE, 
Dummer R: Mitogen-activated protein/extracellular signal-regulated kinase kinase 
inhibition results in biphasic alteration of epidermal homeostasis with keratinocytic 
apoptosis and pigmentation disorders. Clin Cancer Res 2010;16:1058-1064. 
21 Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer 
R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, 
Ribas A, O'Day SJ, Sosman JA, Kirkwood JM, Eggermont AM, Dreno B, Nolop K, Li J, 
Nelson B, Hou J, Lee RJ, Flaherty KT, McArthur GA: Improved survival with 
vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364:2507-
2516. 
22 Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, 
Rutkowski P, Blank CU, Miller WH, Jr., Kaempgen E, Martin-Algarra S, Karaszewska 
B, Mauch C, Chiarion-Sileni V, Martin AM, Swann S, Haney P, Mirakhur B, Guckert 
ME, Goodman V, Chapman PB: Dabrafenib in BRAF-mutated metastatic melanoma: a 
multicentre, open-label, phase 3 randomised controlled trial. Lancet 2012;380:358-365. 
23 Frederick DT, Piris A, Cogdill AP, Cooper ZA, Lezcano C, Ferrone CR, Mitra D, 
Boni A, Newton LP, Liu C, Peng W, Sullivan RJ, Lawrence DP, Hodi FS, Overwijk 
WW, Lizee G, Murphy GF, Hwu P, Flaherty KT, Fisher DE, Wargo JA: BRAF inhibition 
is associated with enhanced melanoma antigen expression and a more favorable tumor 
microenvironment in patients with metastatic melanoma. Clin Cancer Res 2013;19:1225-
1231. 
24 Wilmott JS, Long GV, Howle JR, Haydu LE, Sharma RN, Thompson JF, Kefford 
RF, Hersey P, Scolyer RA: Selective BRAF inhibitors induce marked T-cell infiltration 
into human metastatic melanoma. Clin Cancer Res 2012;18:1386-1394. 
25 Whipple CA, Boni A, Fisher JL, Hampton TH, Tsongalis GJ, Mellinger DL, Yan 
S, Tafe LJ, Brinckerhoff CE, Turk MJ, Mullins DW, Fadul CE, Ernstoff MS: The 
mitogen-activated protein kinase pathway plays a critical role in regulating 
immunological properties of BRAF mutant cutaneous melanoma cells. Melanoma Res 
2016;26:223-235. 
26 Gibney GT, Messina JL, Fedorenko IV, Sondak VK, Smalley KS: Paradoxical 
oncogenesis--the long-term effects of BRAF inhibition in melanoma. Nat Rev Clin Oncol 
2013;10:390-399. 
27 Hu-Lieskovan S, Robert L, Homet Moreno B, Ribas A: Combining targeted 
therapy with immunotherapy in BRAF-mutant melanoma: promise and challenges. J Clin 
Oncol 2014;32:2248-2254. 
19 
 
28 Jiang X, Zhou J, Giobbie-Hurder A, Wargo J, Hodi FS: The activation of MAPK 
in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is 
reversible by MEK and PI3K inhibition. Clin Cancer Res 2013;19:598-609. 
 
Page 6: Dummer R. et al. Binimetinib versus dacarbazine in patients with advanced 
NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 
trial_Lancet Oncology Published online March 8, 2017 http://dx.doi.org/10.1016/S1470-
2045(17)30180-8 
 
Page 13: Sulllivan R et al, Hamid O, Gonzalez R, Infante J et al. Safety and Clinical 
Activity of Atezolizumab+ Cobimetinib+ Vemurafenib in BRAFV600 Mutant Metastatic 
Melanoma. Oral presentation, Society of Melanoma Research Congress, Nov. 2016.  
 
 
 Infante J, Kim TM, Friedmann J, Miller WH et al. Safety and Clinical Activity of 
Atezolizumab Combined With Cobimetinibin Metastatic Melanoma. Oral presentation, 
Society of Melanoma Research Congress, Nov. 2016. 
 
